Cathepsin protease activity modulates amyloid load in extracerebral amyloidosis

Journal of Pathology

Volumn 210, Issue 4, 2006, Pages 478-487

  Röcken, Christoph ^a,c   Fandrich M ^b   Stix, B ^c   Tannert, A ^b   Hortschansky, P ^d   Reinheckel, T ^e   Saftig, P ^f   Kahne T ^c   Menard, R ^g   Ancsin, J B ^h   Buhling F ^c,i  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d HANS KNÖLL INSTITUTE   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f UNIVERSITY OF KIEL   (Germany)

^g NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^h QUEEN S UNIVERSITY   (Canada)

ⁱ CARL THIEM KLINIKUM   (Germany)

Author keywords

Amyloid; Cathepsin; Extracerebral; Protease

Indexed keywords

AMYLOID; AMYLOID ENHANCING FACTOR; CATHEPSIN; CATHEPSIN B; CATHEPSIN K; CATHEPSIN L; CHOLESTEROL ESTERASE; CYSTEINE PROTEINASE; HEPARAN SULFATE; HEPARIN; PROTEIN; RECOMBINANT PROTEIN; SILVER NITRATE;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BODY BURDEN; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME DEGRADATION; FEMALE; IN VITRO STUDY; INJECTION; MODULATION; MOLECULAR SIZE; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RODENT; STATISTICAL SIGNIFICANCE; WILD TYPE;

ACUTE-PHASE REACTION; AMYLOIDOSIS; ANIMALS; CATHEPSIN B; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; FEMALE; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED STRAINS; MONOCYTES; PROTEIN DENATURATION; RECOMBINANT PROTEINS; SERUM AMYLOID A PROTEIN; SPLEEN;

EID: 33751541158     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2076     Document Type: Article

References (45)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-596.
2. Hook V, Toneff T, Bogyo M, Greenbaum D, Medzihradszky KF, Neveu J, et al. Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease. Biol Chem 2005;386:931-940.
3. Higuchi M, Iwata N, Saido TC. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. Biochim Biophys Acta 2005;1751:60-67.
4. Häggqvist B, Naslund J, Sletten K, Westermark GT, Mucchiano G, Tjernberg LO, et al. Medin: an integral fragment of aortic smooth muscle cell-produced lactadherin forms the most common human amyloid. Proc Natl Acad Sci USA 1999;96:8669-8674.
5. Kametani F, Tonoike H, Hoshi A, Shinoda T, Kito S. A variant prealbumin-related low molecular weight amyloid fibril protein in familial amyloid polyneuropathy of Japanese origin. Biochem Biophys Res Commun 1984;125:622-628.
6. Mucchiano GI, Haggqvist B, Sletten K, Westermark P. Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J Pathol 2001;193:270-275.
7. Mucchiano GI, Jonasson L, Haggqvist B, Einarsson E, Westermark P. Apolipoprotein A-I-derived amyloid in atherosclerosis. Its association with plasma levels of apolipoprotein A-I and cholesterol. Am J Clin Pathol 2001;115:298-303.
8. Pras M, Prelli F, Franklin EC, Frangione B. Primary structure of an amyloid prealbumin variant in familial polyneuropathy of Jewish origin. Proc Natl Acad Sci USA 1983;80:539-542.
9. Röcken C, Menard R, Bühling F, Vöckler S, Raynes J, Stix B, et al. Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation. Ann Rheum Dis 2005;64:808-815.
10. Stix B, Leber M, Bingemer P, Gross C, Rüschoff J, Fändrich M, et al. Hereditary lattice corneal dystrophy is associated with corneal amyloid deposits enclosing C-terminal fragments of kerato-epithelin. Invest Ophthalmol Vis Sci 2005;46:1133-1139.
11. Westermark P, Mucchiano G, Marthin T, Johnson KH, Sletten K. Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Am J Pathol 1995;147:1186-1192.
12. Röcken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 2002;440:111-122.
13. Müller D, Roessner A, Röcken C. Distribution pattern of matrix metalloproteinases (MMP-1, -2, -3, and -9), tissue inhibitors of matrix metalloproteinases (TIMP-1 and -2), and α2-macroglobulin in cases of generalized AA- and AL amyloidosis. Virchows Arch 2000;437:521-527.
14. Stix B, Kähne T, Sletten K, Raynes J, Roessner A, Röcken C. Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1, -2, and -3. Am J Pathol 2001;159:561-570.
15. Bohne S, Sletten K, Menard R, Bühling F, Vockler S, Wrenger E, et al. Cleavage of AL amyloid proteins and AL amyloid deposits by cathepsins B, K, and L. J Pathol 2004;203:528-537.
16. Röcken C, Stix B, Brömme D, Ansorge S, Roessner A, Bühling F. A putative role for cathepsin K in degradation of AA and AL amyloidosis. Am J Pathol 2001;158:1029-1038.
17. Röcken C, Tautenhahn J, Bühling F, Sachwitz D, Vöckler S, Goette A, et al. Prevalence and pathology of amyloid in atherosclerotic arteries. Arterioscler Thromb Vasc Biol 2006;26:676-677.
18. Halangk W, Lerch MM, Brandt-Nedelev B, Roth W, Ruthenbuerger M, Reinheckel T, et al. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest 2000;106:773-781.
19. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 1998;95:13453-13458.
20. Roth W, Deussing J, Botchkarev VA, Pauly-Evers M, Saftig P, Hafner A, et al. Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J 2000;14:2075-2086.
21. Kisilevsky R, Boudreau L. The kinetics of amyloid deposition. I. The effects of amyloid-enhancing factor and splenectomy. Lab Invest 1983;48:53-59.
22. Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem 1962;10:355-364.
23. Röcken C, Kientsch-Engel R, Mansfeld S, Stix B, Stubenrauch K, Weigle B, et al. Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis. Am J Pathol 2003; 162:1213-1220.
24. Gellermann GP, Appel TR, Tannert A, Radestock A, Hortschansky P, Schroeckh V, et al. Raft lipids as common components of human extracellular amyloid fibrils. Proc Natl Acad Sci USA 2005;102:6297-6302.
25. Chowdhury SF, Sivaraman J, Wang J, Devanathan G, Lachance P, Qi H, et al. Design of noncovalent inhibitors of human cathepsin L. From the 96-residue proregion to optimized tripeptides. J Med Chem 2002;45:5321-5329.
26. SAA) by murine macrophages in vitro. A light- and electronmicroscopic investigation. Amyloid 1997;4:259-273.
27. Yamada T, Fukuda T, Wada A, Itoh Y. Monoclonal antibody-based sensitive enzyme-linked immunosorbent assay for murine serum amyloid A. J Immunoassay 1999;20:223-235.
28. Kaplan B, Hrncic R, Murphy CL, Gallo G, Weiss DT, Solomon A. Microextraction and purification techniques applicable to chemical characterization of amyloid proteins in minute amounts of tissue. Methods Enzymol 1999;309:67-81.
29. Röcken C, Hegenbarth V, Schmitz M, Stix B, Schade G, Mohnert A, et al. Plasmacytoma of the tonsil with AL amyloidosis: evidence of post-fibrillogenic proteolysis of the fibril protein. Virchows Arch 2000;436:336-344.
30. Linke RP. Monoclonal antibodies against amyloid fibril protein AA. Production, specificity, and use for immunohistochemical localization and classification of AA-type amyloidosis. J Histochem Cytochem 1984;32:322-328.
31. Linke RP, Gärtner HV, Michels H. High-sensitivity diagnosis of AA amyloidosis using congo red and immunohistochemistry detects missed amyloid deposits. J Histochem Cytochem 1995;43:863-869.
32. Bühling F, Reisenauer A, Gerber A, Krüger S, Weber E, Brömme D, et al. Cathepsin K - a marker of macrophage differentiation?. J Pathol 2001;195:375-382.
33. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-29.
34. Ancsin JB, Kisilevsky R. The heparin/heparan sulfate-binding site on apo serum amyloid A - implications for the therapeutic intervention of amyloidosis. J Biol Chem 1999;274:7172-7181.
35. Devanathan G, Turnbull JL, Ziomek E, Purisima EO, Menard R, Sulea T. Carboxy-monopeptidase substrate specificity of human cathepsin X. Biochem Biophys Res Commun 2005;329:445-452.
36. Elimova E, Kisilevsky R, Szarek WA, Ancsin JB. Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J 2004;18:1749-1751.
37. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nature Med 1995;1:143-148.
38. Kisilevsky R, Tam SP. Macrophage cholesterol efflux and the active domains of serum amyloid A 2.1. J Lipid Res 2003;44:2257-2269.
39. Tam SP, Flexman A, Hulme J, Kisilevsky R. Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A 2.1. J Lipid Res 2002;43:1410-1420.
40. Westermark GT, Sletten K, Westermark P. Massive vascular AA-amyloidosis: a histologically and biochemically distinctive subtype of reactive systemic amyloidosis. Scand J Immunol 1989;30:605-613.
41. Prelli F, Pras M, Shtrasburg S, Frangione B. Characterization of high molecular weight amyloid A proteins. Scand J Immunol 1991;33:783-786.
42. Baba S, Takahashi T, Kasama T, Shirasawa H. Identification of two novel amyloid A protein subsets coexisting in an individual patient of AA-amyloidosis. Biochim Biophys Acta 1992;1180:195-200.
43. derivation. Amyloid 1996;3:173-176.
44. Levin M, Franklin EC, Frangione B, Pras M. The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils. J Clin Invest 1972;51:2773-2776.
45. Westermark GT, Westermark P, Sletten K. Amyloid fibril protein AA. Characterization of uncommon subspecies from a patient with rheumatoid arthritis. Lab Invest 1987;57:57-64.